Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TONX | 8-K | bullish | 7/10 | TON Strategy Company reported Q2 2026 results showing a dramatic operational turnaround, driven by the TON network's Cat | Aug 11, 2026 |
| NVRI | 8-K | mixed | 6/10 | Enviri reported Q2 2026 adjusted diluted EPS of -$0.63, a 105.4% miss vs the $-0.31 consensus, though this is a GAAP-adj | Aug 11, 2026 |
| TOVX | 8-K | neutral | 4/10 | Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07/share), compared to a $13.1M loss ( | Aug 11, 2026 |
| MREO | 8-K | bullish | 6/10 | Mereo BioPharma entered into an option and license agreement with Sentynl Therapeutics (a Zydus Lifesciences subsidiary) | Aug 11, 2026 |
| CAH | 8-K | neutral | 4/10 | Cardinal Health entered into a new $4.0 billion unsecured revolving credit facility, replacing its existing $2.0 billion | Aug 11, 2026 |
| NGNE | 8-K | bullish | 7/10 | Neurogene reported Q2 2026 financial results, highlighting continued positive Phase 1/2 data for NGN-401 in Rett syndrom | Aug 11, 2026 |
| AUTL | 8-K | bullish | 7/10 | Autolus Therapeutics reported Q2 2026 AUCATZYL net product revenue of $45.7M, up 119% YoY, and raised FY 2026 guidance t | Aug 11, 2026 |
| AMBQ | 8-K | bullish | 7/10 | Ambiq Micro reported record Q2 2026 net sales of $33.9M, up ~90% YoY and beating the $31.5M consensus. GAAP gross margin | Aug 11, 2026 |
| SGMT | 8-K | mixed | 5/10 | Sagimet Biosciences reported Q2 2026 financial results, highlighting a net loss of $13.95 million ($0.26 per share) vers | Aug 11, 2026 |
| ZURA | 8-K | bullish | 6/10 | Zura Bio reported Q2 2026 financial results with a net loss of $26.3M ($0.21/share), wider than the $16.0M loss in Q2 20 | Aug 11, 2026 |
| BCAX | 8-K | mixed | 6/10 | Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensu | Aug 11, 2026 |
| INTS | 8-K | neutral | 5/10 | Intensity Therapeutics reported Q2 2026 results with a net loss of $3.0M, wider than the $2.5M loss in Q2 2025, and cash | Aug 11, 2026 |
| PRLD | 8-K | neutral | 4/10 | Prelude Therapeutics reported Q2 2026 results with a net loss of $13.9M ($0.14/share), narrower than the $31.2M loss in | Aug 11, 2026 |
| IMSR | 8-K | bullish | 7/10 | Terrestrial Energy reported Q2 2026 results with a net loss of $9.4M ($-0.09 EPS), improving from Q1's $10.5M loss and b | Aug 11, 2026 |
| BSIN | 8-K | neutral | 4/10 | Big Sky Industrial reported Q2 2026 revenue of $2.1M (above the prior year's $2.0M) and a narrower net loss of -$2.3M (- | Aug 11, 2026 |
| IMNN | 8-K | neutral | 5/10 | Imunon reported Q2 2026 net loss of $2.8M ($0.54/share), slightly wider than the $2.7M loss in Q2 2025, with operating e | Aug 11, 2026 |
| SFD | 8-K | bearish | 6/10 | Smithfield Foods reported Q2 fiscal 2026 GAAP diluted EPS of $0.60, beating the consensus estimate of $0.60 by 4.0% on a | Aug 11, 2026 |
| STIM | 8-K | bullish | 6/10 | Neuronetics reported Q2 2026 revenue of $41.6M (+9.1% YoY), beating the $40.2M consensus, and EPS of -$0.05, a 59.2% bea | Aug 11, 2026 |
| COYA | 8-K | neutral | 4/10 | Coya Therapeutics reported Q2 2026 financial results with a net loss of $6.6M ($-0.28/share) vs $6.1M ($-0.36/share) in | Aug 11, 2026 |
| JOBY | 8-K | mixed | 6/10 | Joby Aviation has entered into a definitive agreement to acquire Resonant Sciences, a defense technology company, for ap | Aug 11, 2026 |
| KLRS | 8-K | neutral | 4/10 | Kalaris Therapeutics reported Q2 2026 results with a net loss of $11.5M ($-0.48/share), slightly wider than the $11.4M l | Aug 11, 2026 |
| TARA | 8-K | neutral | 4/10 | Protara Therapeutics reported Q2 2026 results with a net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 | Aug 11, 2026 |
| LBRX | 8-K | bullish | 7/10 | LB Pharmaceuticals reported Q2 2026 financial results, with net loss of $51.6M ($1.71/share) vs $4.9M ($13.58/share) a y | Aug 11, 2026 |
| GTBIF | 8-K | bearish | 7/10 | Green Thumb Industries (GTBIF) filed an 8-K reporting that its subsidiary RSLGH entered into an amendment with RYTHM, In | Aug 11, 2026 |
| HBIO | 8-K | mixed | 6/10 | Harvard Bioscience reported Q2 2026 revenue of $22.7M, up 11% YoY, beating the $21.4M consensus estimate. However, GAAP | Aug 11, 2026 |
| AURA | 8-K | bearish | 6/10 | Aura Biosciences reported Q2 2026 results with a net loss of $45.6M, wider than the $27.0M loss in Q2 2025, driven by in | Aug 11, 2026 |
| VG | 8-K | bullish | 7/10 | Venture Global reported Q2 2026 revenue of $4.58B (+48% YoY) and diluted EPS of $0.51, a 1.5% beat vs the $0.50 consensu | Aug 11, 2026 |
| JBI | 8-K | bearish | 6/10 | Janus International Group reported Q2 2026 revenue of $233.5M (+2.4% YoY), slightly below the $239.4M consensus, and GAA | Aug 11, 2026 |
| BWEN | 8-K | neutral | 4/10 | Broadwind reported Q1 2026 EPS of -$0.02, missing the consensus estimate of -$0.01, on revenue that was not explicitly s | Aug 11, 2026 |
| ARMK | 8-K | bullish | 7/10 | Aramark reported strong Q3 fiscal 2026 results, with revenue of $5.06B (+9% YoY) and adjusted EPS of $0.52, beating cons | Aug 11, 2026 |